Literature DB >> 538410

Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Comparison with a computer-matched family sample.

T Ihamäki, K Varis, M Siurala.   

Abstract

Three hundred and one first-degree relatives (series) of 73 gastric carcinoma patients and 358 control relatives (controls) of 73 computer-matched probands from a general population were studied by direct-vision gastric biopsy and functional and immunological examinations. The controls were representative of the series with respect to age, sex, birth and dwelling place, and relationship of the relatives. Series and controls behaved similarly as to total prevalence of gastritis, age and sex distribution of gastritis, serum gastrin level, and circulating gastric antibodies. On the other hand, the total prevalence of hyperplastic polyps, atrophic gastritis of the body and antrum, severe atrophic gastritis of the body, intestinal metaplasia, epithelial atypia, and achlorhydria was significantly higher in the series than in the controls. In subjects below 50 years of age the prevalence of severe atrophic gastritis of the body, intestinal metaplasia, and epithelial atypia was also significantly higher in the series. In addition, the mean age of the subjects with atrophic gastritis, intestinal metaplasia, epithelial atypia, and achlorhydria was lower in the series than in controls; however, significant differences were found only in female subjects with epithelial atypia and atrophic gastritis of the body. The results suggest that the prevalence of signs often considered premalignant is significantly higher in carcinoma relatives than in controls and that these signs show a trend to occur at an earlier age in carcinoma relatives. This could explain the significantly higher than expected death rate from gastric carcinoma in close relatives with this disease, found in the present and in other series.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 538410     DOI: 10.3109/00365527909181408

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  23 in total

Review 1.  Non-steroidal anti-inflammatory drugs and peptic ulcers.

Authors:  C J Hawkey
Journal:  BMJ       Date:  1990-02-03

Review 2.  Prophylaxis against non-steroidal induced upper gastrointestinal side effects.

Authors:  I Barrison
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

3.  Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.

Authors:  T O Kovacs; D Campbell; M Haber; P Rose; D E Jennings; J Richter
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

4.  Prevalence of peptic ulcer in India: an endoscopic and epidemiological study in urban Kashmir.

Authors:  M S Khuroo; R Mahajan; S A Zargar; G Javid; S Munshi
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 5.  Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy.

Authors:  H Nilsson-Ehle
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

6.  Incidence of peptic ulcer disease in Gothenburg, 1985.

Authors:  I M Schöön; D Mellström; A Odén; B O Ytterberg
Journal:  BMJ       Date:  1989-11-04

7.  Objective evaluation of symptomatic alkaline reflux after antrectomy.

Authors:  S Ludwig; A Ippoliti
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

Review 8.  Gastric cancer: pathogenesis, risks, and prevention.

Authors:  Pentti Sipponen
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

9.  Course of antrum and body gastritis in pernicious anemia families.

Authors:  M Kekki; K Varis; H Pohjanpalo; M Isokoski; T Ihamäki; M Siurala
Journal:  Dig Dis Sci       Date:  1983-08       Impact factor: 3.199

10.  Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to Helicobacter pylori.

Authors:  R J Schlemper; S D van der Werf; J P Vandenbroucke; I Biemond; C B Lamers
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.